{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:20:51Z","timestamp":1781076051001,"version":"3.54.1"},"reference-count":33,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:sec id=\"st1\">\n<jats:title>Background<\/jats:title>\n<jats:p>Bullous pemphigoid is the most common subepidermal autoimmune blistering disease. Till now, the reported prognostic factors in bullous pemphigoid vary considerably.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st2\">\n<jats:title>Aims<\/jats:title>\n<jats:p>The purpose of this study was to determine the overall survival rate and prognostic factors in bullous pemphigoid.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st3\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a retrospective cohort study on newly diagnosed bullous pemphigoid patients between July 2001 and November 2019 in a referral unit for autoimmune blistering skin diseases in Romania.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st4\">\n<jats:title>Results<\/jats:title>\n<jats:p>One hundred forty-eight patients were included in the study. The Kaplan-Meier overall survival rates at 1, 3, 5 and 10 years were respectively 74.2% (95% confidence interval, 67.5-81.6%), 53.4% (45.7-62.2%), 43.6% (35.9-53%) and 31.3% (23.5-41.7%). The median follow-up among survivors was 48 months (interquartile range: 11-150). Ninety (60.8%) patients died during the follow-up period; of them, 38 (42.2%) had active disease at the time of death. Advanced age, neurological diseases, valvular heart disease, malignancies, use of statins, skin infections and extensive cutaneous involvement were linked to poorer outcomes, while the use of topical corticosteroids was associated with increased overall survival.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st5\">\n<jats:title>Limitations<\/jats:title>\n<jats:p>This study lacks a control cohort to validate the obtained results. It was conducted in a retrospective manner in a single centre. In addition, indirect immunofluorescence microscopy was not performed in all patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st6\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Beyond ageing and neurological comorbidities, the prognosis of bullous pemphigoid patients was significantly influenced by the presence of skin infections, valvular heart disease, use of statins and extensive cutaneous involvement. Topical corticosteroid treatment was associated with increased survival in these patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijdvl_705_2021","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T09:20:14Z","timestamp":1665652814000},"page":"363-371","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Survival and prognostic factors in bullous pemphigoid: A retrospective cohort study"],"prefix":"10.25259","volume":"89","author":[{"given":"Cristian","family":"Papara","sequence":"first","affiliation":[{"name":"Department of Dermatology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Chiorean","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel-Corneliu","family":"Leucuta","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics and Biostatistics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Baican","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorina","family":"Danescu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassian","family":"Sitaru","sequence":"additional","affiliation":[{"name":"Department of Centre for Biological Signaling Studies (BIOSS), University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Baican","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"10.25259\/IJDVL_705_2021\/ref-1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/s0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_705_2021\/ref-2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: Overview and potential explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.25259\/IJDVL_705_2021\/ref-3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/archderm.141.6.691","article-title":"Prediction of survival for patients with bullous pemphigoid","volume":"141","author":"Joly","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-4","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: Population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"key":"10.25259\/IJDVL_705_2021\/ref-5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1365-2133.2011.10413.x","article-title":"Mortality of bullous pemphigoid in Switzerland: A prospective study","volume":"165","author":"Cort\u00e9s","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-6","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/jdv.12065","article-title":"Mortality of bullous pemphigoid in the first year after diagnosis: A retrospective study in a Spanish medical centre","volume":"28","author":"Gual","year":"2014","journal-title":"J EurAcad Dermatol Venereol"},{"key":"10.25259\/IJDVL_705_2021\/ref-7","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00403-017-1772-x","article-title":"Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland","volume":"309","author":"Kalinska-Bienias","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"10.25259\/IJDVL_705_2021\/ref-9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/archderm.138.7.903","article-title":"Risk factors for lethal outcome in patients with bullous pemphigoid","volume":"138","author":"Rzany","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/bjd.16553","article-title":"Prospective study in bullous pemphigoid: Association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score","volume":"179","author":"Holtsche","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1684\/ejd.2007.0090","article-title":"Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus","volume":"17","author":"Pf\u00fctze","year":"2007","journal-title":"Eur J Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000345625","article-title":"Mortality rate in bullous pemphigoid: A retrospective monocentric cohort study","volume":"225","author":"Cort\u00e9s","year":"2012","journal-title":"Dermatology"},{"key":"10.25259\/IJDVL_705_2021\/ref-13","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1111\/jdv.16363","article-title":"Anti BP180-autoantibody levels at diagnosis correlate with 1-year mortality rates in patients with bullous pemphigoid","volume":"34","author":"Monshi","year":"2020","journal-title":"J EurAcad Dermatol Venereol"},{"key":"10.25259\/IJDVL_705_2021\/ref-14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2014.02.030","article-title":"Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009","volume":"71","author":"Brick","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jaad.2008.07.022","article-title":"Mortality of bullous pemphigoid: An evaluation of 223 patients and comparison with the mortality in the general population in the United States","volume":"59","author":"Parker","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archderm.134.4.465","article-title":"High risk of death in elderly patients with extensive bullous pemphigoid","volume":"134","author":"Roujeau","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00403-017-1736-1","article-title":"Prognostic factors for mortality in patients with bullous pemphigoid: A meta-analysis","volume":"309","author":"Liu","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"10.25259\/IJDVL_705_2021\/ref-18","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/bjd.19611","article-title":"International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid","volume":"184","author":"Masmoudi","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-19","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jaad.2015.01.029","article-title":"Infectious complications in bullous pemphigoid: An analysis of risk factors","volume":"72","author":"Phoon","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-20","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/bjd.12806","article-title":"Mortality of bullous pemphigoid in Singapore: Risk factors and causes of death in 359 patients seen at the National Skin Centre","volume":"170","author":"Cai","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-21","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3389\/fimmu.2020.01607","article-title":"Assessment of the Characteristics and associated factors of infectious complications in bullous pemphigoid","volume":"11","author":"Chen","year":"2020","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_705_2021\/ref-22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1684\/ejd.2012.1906","article-title":"Treatment and mortality rate of bullous pemphigoid in China: A hospital-based study","volume":"23","author":"Zhang","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-23","first-page":"751","article-title":"Survival prognosis in pemphigoid. A cohort analysis of 78 patients","volume":"122","author":"Bernard","year":"1995","journal-title":"Ann Dermatol Venereol"},{"key":"10.25259\/IJDVL_705_2021\/ref-24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11882-014-0491-z","article-title":"Autoimmune valvular carditis","volume":"15","author":"Breed","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.25259\/IJDVL_705_2021\/ref-25","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3389\/fimmu.2019.01407","article-title":"Coagulation and skin autoimmunity","volume":"10","author":"Cugno","year":"2019","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_705_2021\/ref-26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00403-018-1875-z","article-title":"Mortality and risk factors among Israeli bullous pemphigoid patients","volume":"311","author":"Rozenblat","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"10.25259\/IJDVL_705_2021\/ref-27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1365-2133.2011.10386.x","article-title":"Comorbidity profiles among patients with bullous pemphigoid: A nationwide population-based study","volume":"165","author":"Chen","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/bjd.17197","article-title":"Cancer is not a risk factor for bullous pemphigoid: 10-year population-based cohort study","volume":"180","author":"Chen","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-29","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/jid.2014.547","article-title":"Malignancies in pemphigus and pemphigoid diseases","volume":"135","author":"Schulze","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_705_2021\/ref-31","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: The European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_705_2021\/ref-32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jdin.2021.02.002","article-title":"The association between statins and subsequent risk of bullous pemphigoid: A population-based cohort study","volume":"3","author":"Chang","year":"2021","journal-title":"JAAD Int"},{"key":"10.25259\/IJDVL_705_2021\/ref-33","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/survival-and-prognostic-factors-in-bullous-pemphigoid-a-retrospective-cohort-study\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/survival-and-prognostic-factors-in-bullous-pemphigoid-a-retrospective-cohort-study\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T12:17:47Z","timestamp":1682684267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/survival-and-prognostic-factors-in-bullous-pemphigoid-a-retrospective-cohort-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":33,"alternative-id":["10.25259\/IJDVL_705_2021"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_705_2021","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"article-number":"363"}}